Cronos Q1 Earnings Impacted By COVID-19 Related Restrictions

  • Cronos Group Inc CRON reported a Q1 adjusted EBITDA loss of $37.07 million, marginally up from $37.05 million reported a year ago.
  • This slight increase in losses was primarily driven by the rise in sales and marketing costs due to brand development in the U.S. segment and an increase in R&D costs.
  • Sales increased 50% Y/Y to $12.6 million, primarily driven by growth in the adult-use Canadian cannabis market, sales in the Israeli medical cannabis market, and increased sales in the U.S. segment driven by new U.S. hemp-derived CBD products introductions.
  • It was partially offset by strategic price reductions on various adult-use cannabis products in Canada in the second half of 2020.
  • Gross loss narrowed from $6.5 million inQ1 2020 to $2.9 million, also operating loss lowered to $43.5 million from $45 million a year ago.
  • Price Action: CRON shares are up 3.02% at $7.85 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsMarketsBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.